These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24745511)

  • 21. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-sectional and longitudinal associations of sexual function with lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Fwu CW; Kirkali Z; McVary KT; Burrows PK; Eggers PW; Kusek JW
    J Urol; 2015 Jan; 193(1):231-8. PubMed ID: 25150638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study.
    McVary KT; Gange SN; Gittelman MC; Goldberg KA; Patel K; Shore ND; Levin RM; Rousseau M; Beahrs JR; Kaminetsky J; Cowan BE; Cantrill CH; Mynderse LA; Ulchaker JC; Larson TR; Dixon CM; Roehrborn CG
    J Sex Med; 2016 Jun; 13(6):924-33. PubMed ID: 27129767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement: results of a multicentre prospective study.
    Gacci M; Sebastianelli A; Salvi M; De Nunzio C; Tubaro A; Vignozzi L; Corona G; McVary KT; Kaplan SA; Maggi M; Carini M; Serni S
    BJU Int; 2015 Aug; 116(2):271-7. PubMed ID: 25597623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis and proliferation of the prostate cells in men with benign prostatic hyperplasia and concomitant metabolic disorders.
    Rył A; Rotter I; Kram A; Teresiński L; Słojewski M; Dołęgowska B; Lubkowska A; Piasecka M; Laszczyńska M
    Histol Histopathol; 2018 Apr; 33(4):389-397. PubMed ID: 28948599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    McNaughton-Collins M; Barry MJ
    Am J Med; 2005 Dec; 118(12):1331-9. PubMed ID: 16378773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Total Serum Testosterone Level in Healthy Middle-Aged Eugonadal Men.
    Kaplan SA
    J Urol; 2015 Sep; 194(3):734-5. PubMed ID: 26292875
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup.
    Yang TK; Hsieh JT; Chen SC; Chang HC; Yang HJ; Huang KH
    Urology; 2012 Nov; 80(5):1093-7. PubMed ID: 23107400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
    Fukuta F; Masumori N; Mori M; Tsukamoto T
    Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: Metabolic Syndrome Does Not Increase the Risk of Ejaculatory Dysfunction in Patients with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement: An Italian Single-Center Cohort Study.
    Kaplan SA
    J Urol; 2018 Feb; 199(2):320-321. PubMed ID: 29357524
    [No Abstract]   [Full Text] [Related]  

  • 32. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement.
    De Nunzio C; Brassetti A; Proietti F; Deroma M; Esperto F; Tubaro A
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):287-292. PubMed ID: 29203892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis.
    Gacci M; Corona G; Vignozzi L; Salvi M; Serni S; De Nunzio C; Tubaro A; Oelke M; Carini M; Maggi M
    BJU Int; 2015 Jan; 115(1):24-31. PubMed ID: 24602293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.
    Vignozzi L; Gacci M; Maggi M
    Nat Rev Urol; 2016 Feb; 13(2):108-19. PubMed ID: 26754190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
    Speakman M; Batista J; Berges R; Chartier-Kastler E; Conti G; Desgrandchamps F; Dreikorn K; Lowe F; O'Leary M; Perez M; Trachtenberg J; Tubaro A; Meesen B; Smets L; Stoevelaar H
    Prostate Cancer Prostatic Dis; 2005; 8(4):369-74. PubMed ID: 16130013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lower urinary tract symptoms related to benign prostatic hyperplasia and erectile dysfunction: A systematic review].
    Peyronnet B; Seisen T; Phé V; Misrai V; de la Taille A; Rouprêt M
    Presse Med; 2017 Mar; 46(2 Pt 1):145-153. PubMed ID: 27745762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consultation patterns in a community survey of men with benign prostatic hyperplasia.
    Simpson RJ; Lee RJ; Garraway WM; King D; McIntosh I
    Br J Gen Pract; 1994 Nov; 44(388):499-502. PubMed ID: 7538316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.